PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 38/17

A1

(11) International Publication Number: **WO 98/42366**

(43) International Publication Date: 1 October 1998 (01.10.98)

(21) International Application Number: PCT/EP98/01516

(22) International Filing Date: 16 March 1998 (16.03.98)

(30) Priority Data:
MI97A000694 25 March 1997 (25.03.97) IT

(71) Applicant *(for all designated States except US)*: ZETESIS S.P.A. [IT/IT]; Galleria del Corso, 2, I–20122 Milano (IT).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: PANERAL, Alberto [IT/IT]; Galleria del Corso, 2, I–20122 Milano (IT). MERONI, Pier, Luigi [IT/IT]; Galleria del Corso, 2, I–20122 Milano (IT). BARTORELLI, Alberto [IT/IT]; Galleria del Corso, 2, I–20122 Milano (IT).

(74) Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I–20122 Milano (IT).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: THE USE OF PROTEINS EXTRACTABLE FROM ANIMAL ORGANS FOR THE PREPARATION OF MEDICAMENTS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS CHARACTERIZED BY HYPERPRODUCTION OF TUMOR NECROSIS FACTOR (TNF)

(57) Abstract

Proteins extractable with perchloric acid from mammal liver, in particular from goat liver, are capable of lowering blood levels of Tumor Necrosis Factor (TNF) and can be used for the treatment of multiple sclerosis, rheumatoid arthritis, septic shock and other pathologies characterized by TNF hyperproduction.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT

AL	Albania
AM	Armenia
AT	Austria
AU	Australia
AZ	Azerbaijan
BA	Bosnia and Herzegovina
BB	Barbados
BE	Belgium
BF	Burkina Faso
BG	Bulgaria
BJ	Benin
BR	Brazil
BY	Belarus
CA	Canada
CF	Central African Republic
CG	Congo
CH	Switzerland
CI	Côte d'Ivoire
CM	Cameroon
CN	China
CU	Cuba
CZ	Czech Republic
DE	Germany
DK	Denmark
EE	Estonia
ES	Spain
FI	Finland
FR	France
GA	Gabon
GB	United Kingdom
GE	Georgia
GH	Ghana
GN	Guinea
GR	Greece
HU	Hungary
IE	Ireland
IL	Israel
IS	Iceland
IT	Italy
JP	Japan
KE	Kenya
KG	Kyrgyzstan
KP	Democratic People's Republic of Korea
KR	Republic of Korea
KZ	Kazakstan
LC	Saint Lucia
LI	Liechtenstein
LK	Sri Lanka
LR	Liberia
LS	Lesotho
LT	Lithuania
LU	Luxembourg
LV	Latvia
MC	Monaco
MD	Republic of Moldova
MG	Madagascar
MK	The former Yugoslav Republic of Macedonia
ML	Mali
MN	Mongolia
MR	Mauritania
MW	Malawi
MX	Mexico
NE	Niger
NL	Netherlands
NO	Norway
NZ	New Zealand
PL	Poland
PT	Portugal
RO	Romania
RU	Russian Federation
SD	Sudan
SE	Sweden
SG	Singapore
SI	Slovenia
SK	Slovakia
SN	Senegal
SZ	Swaziland
TD	Chad
TG	Togo
TJ	Tajikistan
TM	Turkmenistan
TR	Turkey
TT	Trinidad and Tobago
UA	Ukraine
UG	Uganda
US	United States of America
UZ	Uzbekistan
VN	Viet Nam
YU	Yugoslavia
ZW	Zimbabwe

THE USE OF PROTEINS EXTRACTABLE FROM ANIMAL ORGANS FOR THE PREPARATION OF MEDICAMENTS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS CHARACTERIZED BY HYPERPRODUCTION OF TUMOR NECROSIS FACTOR (TNF)

The present invention relates to the use of proteins extractable from animal organs for the preparation of medicaments for the treatment of pathological conditions characterized by hyperproduction of Tumor Necrosis Factor (TNF).

TNF, also known as cachectin, is a proinflammatory cytokine playing an important role in starting, together with IL-1, the cascade of other cytokines and factors which trigger the immune response in infections and in cancer. This response is paramount for a complete resolution of infections and metastatic processes, but it can occur in an uncontrolled way, thus causing damage to the host. TNF hyperproduction is considered to be involved in a number of pathological conditions, such as septic shock, tumor cachexia, autoimmune diseases (rheumatoid arthritis, multiple sclerosis), meningococcal septicemia, Chron's disease, etc..

WO 92/10197 disclosed protein fractions extractable with perchloric acid from organs of mammals, and their use as anticancer agents. Within these fractions, three main components could be identified, having molecular weights of 50, 14 and 10 KDa on gel electrophoresis. Hereinafter, the purified extract containing these three components will be referred to as UK 101. The sequence of the 14 KDa component, which is the main, if not the only protein, responsible for the described activities,

is reported in WO 96/02567 and it has turned out to be related to that described by other authors (Levy-Favatier, Eur. Biochem. 1903, 212 (3) 665-73) who have assumed that the novel identified sequences belong to the family of the proteins known as chaperonins, to which the HSPs (Heat Shock Proteins) themselves belong.

The proteins described in WO 92/10197 and those of WO 96/02567 (hereinafter referred to as UK 114) show properties not previously observed in chaperonins or analogous proteins. Now it has been found, in particular, that said proteins are capable of significantly lowering TNF blood levels and therefore they can be used for the treatment of pathological conditions characterized by hyperproduction of TNF.

The invention relates particularly to the use of the purified protein UK 114.

Moreover the invention comprises the use of proteins showing high homology to UK 114, of at least 80%, especially of 90% or more.

The activity of the proteins UK 101 and UK 114 has been demonstrated in vitro, on mononuclear leukocytes from peripheral blood and in vivo, by evaluating the effect of the administration of UK 101 on the production by mouse splenocytes as reported hereinafter.

In vitro tests

Mononuclear leukocytes from peripheral blood (PBMC), at a concentration of 1 million/ml, were stimulated in vitro with lipopolysaccharide (100/ ng/ml), for 4 hours, in the absence or in the presence of UK 114 (1 µg/ml and 10 µg/ml).

TNF levels were measured by ELISA.

Results

TNF production by PBMC was inhibited by the addition of UK 114 in vitro.

The decrease was by 90% with a 1 µg/ml dose of UK 114 and by 70% with a 10 µg/ml dose of UK 114.

In vivo tests

Treatment:

Mice were treated with 100 µg/mouse of UK 101 on alternate days for 15 days (7 injections).

TNF has been measured 48 hours after the first injection and 48 hours after the last administration.

Preparation of the cells and TNF measurements

Splenocytes (4 x 10^6 cells/ml) were incubated in the presence of 10 µg/ml of the polyclonal mitogen Concanavalin-A (With-A), for 48 hours, at 37°C, 5% CO_2.

The amount of produced TNF released into the supernatant has been evaluated using an immunoenzymatic method (ELISA).

Results

Treatment with UK 101 significantly decreased TNF production by mouse splenocytes. The effect is evident 48 hours after the first administration and it is still present even 48 hours after the seventh administration.

TNF, pg/ml

	physiological saline	UK-101
48 hours after the 1st administration	387 ± 72	247 ± 30°
48 hours after the 7th administration	366 ± 46	264 ± 76,1°

° = p value

Therefore, UK 101 and UK 114 are capable of modifying the course of, or preventing, pathological conditions characterized by TNF hyperproduction, such as multiple sclerosis, rheumatoid arthritis, tumor forms, septic shock, Chron's disease, etc..

The proteins of the invention can be administered by means of suitable formulations, preferably injectable forms.

The procedure of administration (doses, frequency of administration, etc.) will be determined according to the circumstances, depending on a number of factors such as the condition of the patient, stage of the disease. Nevertheless a daily dosage ranging from 1 to 100 mg will be suitable.

TABLE

Met Ser Glu Asn Ser Glu Glu Pro Val Gly Glu Ala Lys Ala
1 5 10

Pro Ala Ala Ile Gly Pro Tyr Ser Gln Ala Val Leu Val Asp
15 20 25

Arg Thr Ile Tyr Ile Ser Gly Gln Leu Gly Met Asp Pro Ala
30 35 40

Ser Gly Gln Leu Val Pro Gly Gly Val Val Glu Glu Ala Lys
45 50 55

Gln Ala Leu Thr Asn Ile Gly Glu Ile Leu Lys Ala Ala Gly
60 65 70

Cys Asp Phe Thr Asn Val Val Lys Ala Thr Val Leu Leu Ala
75 80

Asp Ile Asn Asp Phe Ser Ala Val Asn Asp Val Tyr Lys Gln
85 90 95

Tyr Phe Gln Ser Ser Phe Pro Ala Arg Ala Ala Tyr Gln Val
100 105 110

Ala Ala Leu Pro Lys Gly Gly Arg Val Glu Ile Glu Ala Ile
115 120 125

Ala Val Gln Gly Pro Leu Thr Thr Ala Ser Val
130 135

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: Zetesis s.p.a.

(B) STREET: Galleria del Corso 2

(C) CITY: Milano

(E) COUNTRY: Italy

(F) POSTAL CODE (ZIP): 20122

(ii) TITLE OF INVENTION: The use of proteins extractable from animal organs for the preparation of medicaments for the treatment of pathological conditions characterized by hyperproduction of tumor necrosis factor (TNF)

(iii) NUMBER OF SEQUENCES: 1

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 137 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Met Ser Glu Asn Ser Glu Glu Pro Val Gly Glu Ala Lys Ala
1 5 10

Pro Ala Ala Ile Gly Pro Tyr Ser Gln Ala Val Leu Val Asp
15 20 25

Arg Thr Ile Tyr Ile Ser Gly Gln Leu Gly Met Asp Pro Ala
30 35 40

Ser Gly Gln Leu Val Pro Gly Gly Val Val Glu Glu Ala Lys
45 50 55

Gln Ala Leu Thr Asn Ile Gly Glu Ile Leu Lys Ala Ala Gly
60 65 70

Cys Asp Phe Thr Asn Val Val Lys Ala Thr Val Leu Leu Ala
75 80

Asp Ile Asn Asp Phe Ser Ala Val Asn Asp Val Tyr Lys Gln
85 90 95

Tyr Phe Gln Ser Ser Phe Pro Ala Arg Ala Ala Tyr Gln Val
100 105 110

Ala Ala Leu Pro Lys Gly Gly Arg Val Glu Ile Glu Ala Ile
115 120 125

Ala Val Gln Gly Pro Leu Thr Thr Ala Ser Val
130 135

CLAIMS

1. The use of proteins extractable with perchloric acid from mammal liver, for the preparation of medicaments for the prevention and the treatment of pathologies characterized by TNF hyperproduction.

2. The use according to claim 1, wherein the protein has the following sequence:

Met Ser Glu Asn Ser Glu Glu Pro Val Gly Glu Ala Lys Ala
1 5 10

Pro Ala Ala Ile Gly Pro Tyr Ser Gln Ala Val Leu Val Asp
15 20 25

Arg Thr Ile Tyr Ile Ser Gly Gln Leu Gly Met Asp Pro Ala
30 35 40

Ser Gly Gln Leu Val Pro Gly Gly Val Val Glu Glu Ala Lys
45 50 55

Gln Ala Leu Thr Asn Ile Gly Glu Ile Leu Lys Ala Ala Gly
60 65 70

Cys Asp Phe Thr Asn Val Val Lys Ala Thr Val Leu Leu Ala
75 80

Asp Ile Asn Asp Phe Ser Ala Val Asn Asp Val Tyr Lys Gln
85 90 95

Tyr Phe Gln Ser Ser Phe Pro Ala Arg Ala Ala Tyr Gln Val
100 105 110

Ala Ala Leu Pro Lys Gly Gly Arg Val Glu Ile Glu Ala Ile
115 120 125

Ala Val Gln Gly Pro Leu Thr Thr Ala Ser Val
130 135

3. The use according to claim 1, wherein the proteins used have a homology of at least 80% to the protein of claim 2.

INTERNATIONAL SEARCH REPORT

Inte Jonal Application No
PCT/EP 98/01516

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K38/17

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 96 02567 A (ZETESIS SPA) 1 February 1996 cited in the application see page 1 - page 5 --- -/--	1-3

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of theinternational search	Date of mailing of the international search report
21 August 1998	04/09/1998

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Masturzo, P

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Inte ional Application No
PCT/EP 98/01516

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CHEMICAL ABSTRACTS, vol. 119, no. 7, 16 August 1993 Columbus, Ohio, US; abstract no. 65937, XP002075248 & F LEVY-FAVATIER ET AL.: "Characterization, purifiication and cDNA cloning of a rat perchloric-acid-soluble 23 kDa protein present only in liver and kidney " EUR. J. BIOCHEM., vol. 212, no. 3, March 1993, pages 665-673, cited in the application see abstract	1-3
Y	WO 96 10039 A (PEPTIDE THERAPEUTICS LIMITED) 4 April 1996 see the whole document	1-3
Y	GB 2 251 186 A (GATZ & BROMLEY) 1 July 1992 see the whole document	1-3
E	WO 98 11909 A (ZETESIS) 26 March 1998 see the whole document	1-3

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Jonal Application No
PCT/EP 98/01516

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9602567 A	01-02-1996	IT 1270618 B	07-05-1997
		AU 3077995 A	16-02-1996
		BR 9508382 A	23-12-1997
		CA 2194861 A	01-02-1996
		CN 1152924 A	25-06-1997
		CZ 9700069 A	13-08-1997
		EP 0770093 A	02-05-1997
		FI 970097 A	06-03-1997
		HU 76328 A	28-08-1997
		JP 10502814 T	17-03-1998
		NO 970114 A	05-03-1997
		US 5792744 A	11-08-1998
		ZA 9505837 A	21-02-1996
WO 9610039 A	04-04-1996	AU 3571095 A	19-04-1996
		CA 2200338 A	04-04-1996
		EP 0804475 A	05-11-1997
GB 2251186 A	01-07-1992	NONE	
WO 9811909 A	26-03-1998	IT MI961919 A	18-03-1998
		IT MI961920 A	18-03-1998
		IT MI961921 A	18-03-1998
		IT MI961922 A	18-03-1998
		AU 4774797 A	14-04-1998